Enzyme specifically linked to aggressive prostate cancer has been identified by researchers. Their study, published in the Dec. 18 online edition of Molecular Cancer Research is the first to link the enzyme PRSS3 to prostate cancer.
"This molecule is a protease, which means it digests other molecules. Our data suggests PRSS3 activity changes the environment around prostate cancer cells — perhaps by freeing them from surrounding tissue — to promote malignancy and invasiveness," says the study's senior investigator, Evette Radisky, Ph.D., a cancer biologist in the Mayo Clinic Cancer Center. "I don't think PRSS3 is the only factor involved in driving aggressive prostate cancer, but it may be significant for a certain subset of this cancer — the kind that is potentially lethal," she says.
Dr. Radisky and five colleagues at Mayo Clinic in Florida made the discovery by investigating publicly available databases, derived from clinical studies, which contain data on molecules that are upregulated — irregularly switched on — in cancer. They had previously discovered a link between the protease and the earlier stages of breast cancer.
The research team wanted to see if any other cancer abnormally expresses this protease, and at what stages so they mined multiple databases.
"The link between PRSS3 activity and aggressive prostate cancer jumped out at us," Dr. Radisky says. "We found a definitive trend of increasing PRSS3 expression with cancer progression."
Then, in mice models of prostate cancer, the researchers demonstrated that expression of the protease was critical for prostate cancer metastasis. Cancer did not spread in mice in which PRSS3 was silenced.
The group had earlier crystallized the structure of the PRSS3 protease, and discovered a place on the enzyme where a small protein therapeutic could bind to plug up the "scissoring" action of the molecule.
"The protease has an active site that breaks down other proteins, and our inhibiting agent sticks to the site, shutting it down," Dr. Radisky says.
The researchers say their finding suggests several possible future clinical applications.
We might be able to test prostate cancer patients for the presence of this molecule, to help identify those who are most at risk for aggressive cancer," she says.
And the researchers' prototype drug provides a template upon which to build an agent that can be used to treat these same patients, Dr. Radisky says. "Our inhibitor does not have the characteristics we need for a clinically useful drug. But it puts us on the right path to develop one."
Other study authors are Alexandria Hockla, Erin Miller, Moh'd A. Salameh, Ph.D., John A. Copland, Ph.D., and Derek Radisky, Ph.D., all from the Department of Cancer Biology at the Mayo Clinic campus in Florida. The authors declare no conflicts of interest.
The study was funded by grants from the Bankhead-Coley Florida Biomedical Research Program, the Department of Defense, and the National Cancer Institute.